Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

British Journal of Clinical Pharmacology

Volumn 50, Issue 2, 2000, Pages 108-115

  Khaliq, Yasmin ^a,b   Gallicano, Keith ^a,b,c   Seguin, Isabelle ^a   Fyke, Kathryn ^a   Carignan, Germain ^a   Bulman, Dennis ^a,b   Badley, Andrew ^a,b   Cameron, D William ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Axelson Biopharma Research Inc   (Canada)

Author keywords

CYP2C19; Liver disease; Nelfinavir; Pharmacokinetics

Indexed keywords

ACICLOVIR; AG 1402; AZITHROMYCIN; BECLOMETASONE; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 2C19; DRUG METABOLITE; ETHAMBUTOL; FLUCONAZOLE; FUROSEMIDE; LAMIVUDINE; M 8; METHADONE; NELFINAVIR; PYRAZINAMIDE; RIFABUTIN; SALBUTAMOL; SAQUINAVIR; SPIRONOLACTONE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CONFIDENCE INTERVALS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; LIVER DISEASES; MALE; MIXED FUNCTION OXYGENASES; NELFINAVIR;

EID: 0033866253     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00238.x     Document Type: Article

References (24)

1. 1 Tucker GT. Alteration of drug disposition in liver impairment. Br J Clin Pharmacol 1998; 46: 351-359.
2. 2 Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999; 13: 870-871.
3. 3 Hilts AD, Fish DN. Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Am J Health-Syst Pharm 1998; 55: 2528-2533.
4. 4 Zhang MH, Pithavala YK, Lee CA, et al. Apparent genetic polymorphism in nelfinavir metabolism: evaluation of clinical relevance (abstract no. 264). In Program and Abstracts of the 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France, 1998.
5. 5 Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother 1999; 33: 325-339.
6. 6 Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998; 12: 1243-1244.
7. 7 Merry C, Barry M, Ryan M, et al. A study of the pharmacokinetics of repetitive dosing with nelfinavir (abstract no. 831). In Program and Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, 1999.
8. 8 Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate (abstract no. 3035). In Abstracts of the 12th American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Francisco, CA, 1998.
9. 9 Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64: 8-17.
10. 10 Rost KL, Brockmöller J, Esdorn F, Roots I. Phenocopies of poor metabolizes of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23: 268-277.
11. 11 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
12. 12 Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286: 1490-1495.
13. 13 de Morais SMF, Wilkinson GR, Blaisdell J, Meyer US, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
14. 14 Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-561.
15. 15 Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12: F111-F115.
16. 16 Merry C, Barry MG, Mulcahy F, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12: 1163-1167.
17. 17 Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250: 255-262.
18. 18 Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 1999; 43: 1686-1692.
19. 19 Halifax KL, Lindup WE, Barry MG, Wiltshire HR, Back DJ. Binding of the HIV protease inhibitor saquinavir to human plasma proteins. Br J Clin Pharmacol 1998; 46: 291P.
20. 20 MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989; 16: 65-73.
21. 21 Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic interaction of nelfinavir with half-dose rifabutin (abstract no. B203). Can J Infect Dis 1999; 10(Suppl B): 21B.
22. 22 Ferguson RJ, de Morais SM, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284: 356-361.
23. 23 Ibeanu GC, Blaisdell J, Ghanayem BI, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8: 129-135.
24. 24 Ibeanu GC, Blaisdell J, Ferguson RJ, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1998; 290: 635-640.